#Belgium #funding #VolitionRx #Namur

VolitionRx Secures Significant Funding for Epigenetic Advancements

VolitionRx Limited, a leading name in epigenetics, has recently received a substantial €2.0 million in funding from regional government agencies in Belgium, specifically Namur Invest and Wallonie Entreprendre S.A. This funding marks a pivotal moment for the company as it continues to innovate and advance its Nu.Q® product portfolio.

Aiming to Enhance Research and Development

With the new funding, VolitionRx plans to accelerate its regulatory transition program for the Nu.Q® NETs, moving from IVDD to IVDR, while also focusing on the development of a Lateral Flow product. This initiative aims to improve access to its Nu.Q® NETs product in low-income countries, showcasing the company’s commitment to global healthcare and accessibility.

Mr. Nicolas Delahaye, representing Namur Invest, expressed his enthusiasm for the continuing collaboration with Volition, highlighting the innovative contributions made by the Belgian team. He emphasized the role of this funding in expanding their manufacturing capabilities and bolstering Research and Development efforts in Wallonia.

Similarly, Mr. Géry Lefebvre from Wallonie Entreprendre S.A. reiterated the organization's mission to support innovative firms like VolitionRx. He acknowledged the firm’s impressive technological platform and intellectual property portfolio developed over the past fifteen years, underscoring the importance of supporting key moments in clinical validation and commercialization.

Gratitude and Vision for the Future

Dr. Gaetan Michel, COO of Volition, expressed a deep appreciation for the financial endorsement from Namur Invest and Wallonie Entreprendre S.A. He noted that this funding is a critical step in Volition’s financing strategy, as it exemplifies the company’s dedication to acquiring non-dilutive funding. This type of financing is advantageous, providing essential cash flow without impacting shareholding.

To date, the total amount of non-dilutive funding from all sources surpasses $25 million, which further cements Volition's financial foundation and its capability to innovatively advance in the epigenetics field throughout the year. The funding will be disbursed in tranches, contingent on specific timelines and milestones within the next twelve months, ensuring performance-driven support for Volition's ongoing projects.

Commitment to Early Detection and Improved Outcomes

VolitionRx is at the forefront of epigenetics advancements, aiming to enhance the detection of life-threatening diseases. The company is dedicated to developing simple and affordable blood tests that can significantly aid in the early detection of various ailments, including cancers and conditions related to NETosis. Through its innovative approach, Volition ensures that early detection could greatly improve life longevity and quality for patients worldwide.

The company's research and development activities flourish primarily in Belgium with a dedicated innovation lab and operational offices in the United States and the United Kingdom. This strategic placement allows Volition to foster global collaborations and expand its influence in the biomedical field.

Looking Ahead

As VolitionRx moves forward with the support of this latest funding, the company is poised to reach significant milestones that will not only enhance its product offerings but also contribute to patient care enhancements in the broader healthcare system. The dedication to combining innovation with practical healthcare solutions illustrates Volition's commitment to harnessing science for transformative outcomes in disease management and early detection.

In conclusion, the non-dilutive funding from Belgian government agencies not only reinforces VolitionRx's financial stability but also underscores the potential impact of its health-focused innovations. The future looks bright as VolitionRx continues to grow and evolve in its mission to make life-saving diagnostics accessible for all.